MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 425, Issue 2, 2012, Pages 127-133

  Huang, Lin ^a,b   Dai, Ting ^c   Lin, Xi ^a   Zhao, Xiaohui ^a   Chen, Xiuting ^a   Wang, Chanjuan ^c   Li, Xinghua ^a   Shen, Huiyong ^b   Wang, Xi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; Metastasis; MiR 224; RKIP

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; INTERSTITIAL COLLAGENASE; MATRIGEL; MICRORNA; MICRORNA 224; OSTEOPONTIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER CELL; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; WOUND HEALING;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; UP-REGULATION;

EID: 84865379684     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.025     Document Type: Article

References (41)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2:533-543.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
3. Porter P. "Westernizing" women's risks? Breast cancer in lower-income countries. N. Engl. J. Med. 2008, 358:213-216.
4. Lorusso G., Ruegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012, 22:226-233.
5. J.H. Lee, A. Nan, Combination drug delivery approaches in metastatic breast cancer, J. Drug. Deliv. 2012 915375.
6. Mulholland D.J., Kobayashi N., Ruscetti M., Zhi A., Tran L.M., Huang J., Gleave M., Wu H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 2012, 72:1878-1889.
7. Carnero A. The PKB/AKT pathway in cancer. Curr. Pharm. Des. 2010, 16:34-44.
8. Antoun G., Cannon P.B., Cheng H.Y. Regulation of MAPK/ERK signaling and photic entrainment of the suprachiasmatic nucleus circadian clock by Raf kinase inhibitor protein. J. Neurosci. 2012, 32:4867-4877.
9. Deiss K., Kisker C., Lohse M.J., Lorenz K. Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein coupled receptor kinase (GRK) 2. J. Biol. Chem. 2012, 287:23407-23417.
10. Bonavida B., Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-kappaB/Snail/YY1/RKIP/PTEN Circuitry. Crit. Rev. Oncog. 2011, 16:211-226.
11. Ren G., Baritaki S., Marathe H., Feng J., Park S., Beach S., Bazeley P.S., Beshir A.B., Fenteany G., Mehra R., Daignault S., Al Mulla F., Keller E., Bonavida B., de la Serna I., Yeung K.C. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res. 2012, 72:3091-3104.
12. E. Bevilacqua, C.A. Frankenberger, M.R. Rosner, RKIP Suppresses Breast Cancer Metastasis to the Bone by Regulating Stroma-Associated Genes, Int. J. Breast Cancer 2012 124704.
13. Fujimori Y., Inokuchi M., Takagi Y., Kato K., Kojima K., Sugihara K. Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res. 2012, 31:30.
14. Birner P., Jesch B., Schultheis A., Schoppmann S.F. RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin. Exp. Metastasis. 2012, 29:551-559.
15. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8:341-352.
16. Dangi-Garimella S., Yun J., Eves E.M., Newman M., Erkeland S.J., Hammond S.M., Minn A.J., Rosner M.R. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 2009, 28:347-358.
17. Yun J., Frankenberger C.A., Kuo W.L., Boelens M.C., Eves E.M., Cheng N., Liang H., Li W.H., Ishwaran H., Minn A.J., Rosner M.R. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. Embo. J. 2011, 30:4500-4514.
18. Boire A., Covic L., Agarwal A., Jacques S., Sherifi S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
19. Zhou Z., Chen Z.W., Yang X.H., Shen L., Ai X.H., Lu S., Luo Q.Q. Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer. J Exp Clin Cancer Res. 2012, 31:34.
20. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell. Mol. Med. 2010, 14:2037-2044.
21. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
22. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27:5848-5856.
23. X.B. Shi, L. Xue, J. Yang, A.H. Ma, J. Zhao, M. Xu, C.G. Tepper, C.P. Evans, H.J. Kung, R.W. deVere White, An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells, Proc Natl Acad Sci U S A 104 (2007) 19983-19988.
24. Musiyenko A., Bitko V., Barik S. Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. (Berlin) 2008, 86:313-322.
25. Lu Z., Liu M., Stribinskis V., Klinge C.M., Ramos K.S., Colburn N.H., Li Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
26. Pollari S., Leivonen S.K., Perala M., Fey V., Kakonen S.M., Kallioniemi O. Identification of MicroRNAs Inhibiting TGF-beta-Induced IL-11 Production in Bone Metastatic Breast Cancer Cells. PLoS One 2012, 7:e37361.
27. Tjensvoll K., Svendsen K.N., Reuben J.M., Oltedal S., Gilje B., Smaaland R., Nordgard O. MiRNA expression profiling for identification of potential breast cancer biomarkers. Biomarkers 2012, 17:463-470.
28. Khew-Goodall Y., Goodall G.J. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010, 12:209-211.
29. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
30. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., Teruya-Feldstein J., Bell G.W., Weinberg R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28:341-347.
31. Pedrioli D.M., Karpanen T., Dabouras V., Jurisic G., van de Hoek G., Shin J.W., Marino D., Kalin R.E., Leidel S., Cinelli P., Schulte-Merker S., Brandli A.W., Detmar M. MiR-31 functions as a negative regulator of lymphatic vascular lineage-specific differentiation in vitro and vascular development in vivo. Mol Cell Biol. 2010, 30:3620-3634.
32. Sachdeva M., Mo Y.Y. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 2010, 70:378-387.
33. Feng R., Chen X., Yu Y., Su L., Yu B., Li J., Cai Q., Yan M., Liu B., Zhu Z. MiR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010, 298:50-63.
34. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401:173-177.
35. Gregory R.I., Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005, 65:3509-3512.
36. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
37. Wang Y., Lee C.G. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?. Epigenomics 2011, 3:235-243.
38. Boguslawska J., Wojcicka A., Piekielko-Witkowska A., Master A., Nauman A. MiR-224 targets the 3'UTR of type 1 5'-iodothyronine deiodinase possibly contributing to tissue hypothyroidism in renal cancer. PLoS One 2011, 6:e24541.
39. Mencia N., Selga E., Noe V., Ciudad C.J. Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem. Pharmacol. 2011, 82:1572-1582.
40. Mees S.T., Mardin W.A., Sielker S., Willscher E., Senninger N., Schleicher C., Colombo-Benkmann M., Haier J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann. Surg. Oncol. 2009, 16:2339-2350.
41. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.